A phase II, multi-center study of a new non-cytotoxic A3 adenosine receptor agonist CF101, dose-finding (randomized blinded) in patients (pts)with refractory metastatic colorectal cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 3153-3153 ◽  
Author(s):  
S. M. Stemmer ◽  
A. Shani ◽  
B. Klein ◽  
M. H. Silverman ◽  
I. Lorber ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Adenosine Receptor ◽  
Receptor Agonist ◽  
Dose Finding ◽  
Adenosine Receptor Agonist ◽  
A3 Adenosine Receptor ◽  
Multi Center Study ◽  
Center Study

scholarly journals CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver

2011 ◽  
Vol 226 (9) ◽  
pp. 2438-2447 ◽  
Author(s):  
S. Cohen ◽  
S.M. Stemmer ◽  
G. Zozulya ◽  
A. Ochaion ◽  
R. Patoka ◽  
...  
Keyword(s):  
Adenosine Receptor ◽  
Receptor Agonist ◽  
Adenosine Receptor Agonist ◽  
A3 Adenosine Receptor ◽  
Anti Inflammatory

A3 Adenosine Receptor Agonist Inhibited Survival of Breast Cancer Stem Cells via GLI-1 and ERK1/2 Pathway

2017 ◽  
Vol 118 (9) ◽  
pp. 2909-2920 ◽  
Author(s):  
Seyyed Mehdi Jafari ◽  
Mojtaba Panjehpour ◽  
Mahmoud Aghaei ◽  
Hamid Reza Joshaghani ◽  
Seyed Ehsan Enderami
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Adenosine Receptor ◽  
Receptor Agonist ◽  
Breast Cancer Stem Cells ◽  
Adenosine Receptor Agonist ◽  
A3 Adenosine Receptor ◽  
Gli 1
Sign in / Sign up

Export Citation Format

Share Document